583 related articles for article (PubMed ID: 27776446)
1. Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections.
Bodier-Montagutelli E; Morello E; L'Hostis G; Guillon A; Dalloneau E; Respaud R; Pallaoro N; Blois H; Vecellio L; Gabard J; Heuzé-Vourc'h N
Expert Opin Drug Deliv; 2017 Aug; 14(8):959-972. PubMed ID: 27776446
[TBL] [Abstract][Full Text] [Related]
2. Phage therapy for respiratory infections.
Chang RYK; Wallin M; Lin Y; Leung SSY; Wang H; Morales S; Chan HK
Adv Drug Deliv Rev; 2018 Aug; 133():76-86. PubMed ID: 30096336
[TBL] [Abstract][Full Text] [Related]
3. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy.
Malik DJ; Sokolov IJ; Vinner GK; Mancuso F; Cinquerrui S; Vladisavljevic GT; Clokie MRJ; Garton NJ; Stapley AGF; Kirpichnikova A
Adv Colloid Interface Sci; 2017 Nov; 249():100-133. PubMed ID: 28688779
[TBL] [Abstract][Full Text] [Related]
4. Respirable bacteriophages for the treatment of bacterial lung infections.
Hoe S; Semler DD; Goudie AD; Lynch KH; Matinkhoo S; Finlay WH; Dennis JJ; Vehring R
J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):317-35. PubMed ID: 23597003
[TBL] [Abstract][Full Text] [Related]
5. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
Luong T; Salabarria AC; Roach DR
Clin Ther; 2020 Sep; 42(9):1659-1680. PubMed ID: 32883528
[TBL] [Abstract][Full Text] [Related]
6. [Phage therapy for respiratory infections].
Mitropoulou G; Gijs PJ; Koutsokera A; Sauty A; Blanchon S; Csajka C; Brunet JF; Resch G; Guery B; Von Garnier C
Rev Med Suisse; 2022 Nov; 18(804):2150-2156. PubMed ID: 36382975
[TBL] [Abstract][Full Text] [Related]
7. Reapproaching Old Treatments: Considerations for PK/PD Studies on Phage Therapy for Bacterial Respiratory Infections.
Schmalstig AA; Freidy S; Hanafin PO; Braunstein M; Rao GG
Clin Pharmacol Ther; 2021 Jun; 109(6):1443-1456. PubMed ID: 33615463
[TBL] [Abstract][Full Text] [Related]
8. Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.
Wang X; Xie Z; Zhao J; Zhu Z; Yang C; Liu Y
Front Cell Infect Microbiol; 2021; 11():758392. PubMed ID: 34938668
[TBL] [Abstract][Full Text] [Related]
9. Towards Inhaled Phage Therapy in Western Europe.
Wienhold SM; Lienau J; Witzenrath M
Viruses; 2019 Mar; 11(3):. PubMed ID: 30909579
[TBL] [Abstract][Full Text] [Related]
10. Bacteriophage therapy: an overview and the position of Italian Society of Infectious and Tropical Diseases.
Cesta N; Di Luca M; Corbellino M; Tavio M; Galli M; Andreoni M
Infez Med; 2020 Sep; 28(3):322-331. PubMed ID: 32920567
[TBL] [Abstract][Full Text] [Related]
11. Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains.
Rohde C; Resch G; Pirnay JP; Blasdel BG; Debarbieux L; Gelman D; Górski A; Hazan R; Huys I; Kakabadze E; Łobocka M; Maestri A; Almeida GMF; Makalatia K; Malik DJ; Mašlaňová I; Merabishvili M; Pantucek R; Rose T; Štveráková D; Van Raemdonck H; Verbeken G; Chanishvili N
Viruses; 2018 Apr; 10(4):. PubMed ID: 29621199
[TBL] [Abstract][Full Text] [Related]
12. Phage therapy efficacy: a review of the last 10 years of preclinical studies.
Melo LDR; Oliveira H; Pires DP; Dabrowska K; Azeredo J
Crit Rev Microbiol; 2020 Feb; 46(1):78-99. PubMed ID: 32091280
[TBL] [Abstract][Full Text] [Related]
13. Phage Therapy for Respiratory Infections: Opportunities and Challenges.
Khosravi A; Chen Q; Echterhof A; Koff JL; Bollyky PL
Lung; 2024 Jun; 202(3):223-232. PubMed ID: 38772946
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy.
Ryan EM; Gorman SP; Donnelly RF; Gilmore BF
J Pharm Pharmacol; 2011 Oct; 63(10):1253-64. PubMed ID: 21899540
[TBL] [Abstract][Full Text] [Related]
15. Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections.
Iszatt JJ; Larcombe AN; Chan HK; Stick SM; Garratt LW; Kicic A
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578390
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.
Dąbrowska K; Abedon ST
Microbiol Mol Biol Rev; 2019 Nov; 83(4):. PubMed ID: 31666296
[TBL] [Abstract][Full Text] [Related]
17. Bacteriophage therapy for management of bacterial infections in veterinary practice: what was once old is new again.
Squires RA
N Z Vet J; 2018 Sep; 66(5):229-235. PubMed ID: 29925297
[TBL] [Abstract][Full Text] [Related]
18. Formulation strategies for bacteriophages to target intracellular bacterial pathogens.
Yan W; Banerjee P; Xu M; Mukhopadhyay S; Ip M; Carrigy NB; Lechuga-Ballesteros D; To KKW; Leung SSY
Adv Drug Deliv Rev; 2021 Sep; 176():113864. PubMed ID: 34271022
[TBL] [Abstract][Full Text] [Related]
19. Delivering phage therapy per os: benefits and barriers.
Zelasko S; Gorski A; Dabrowska K
Expert Rev Anti Infect Ther; 2017 Feb; 15(2):167-179. PubMed ID: 27885865
[TBL] [Abstract][Full Text] [Related]
20. Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages.
Cisek AA; Dąbrowska I; Gregorczyk KP; Wyżewski Z
Curr Microbiol; 2017 Feb; 74(2):277-283. PubMed ID: 27896482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
